The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues

Cancer Immunology, Immunotherapy

Volumn 61, Issue 7, 2012, Pages 1101-1111

  Tel, Jurjen ^a   Hato, Stanleyson V ^a   Torensma, Ruurd ^a   Buschow, Sonja I ^a   Figdor, Carl G ^a   Lesterhuis, W Joost ^a   De Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood DC subsets; Oxaliplatin; PD L1; TLR

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 4; INTERLEUKIN 6; OXALIPLATIN; PROGRAMMED DEATH 1 LIGAND 1; STAT1 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; DENDRITIC CELLS; HUMANS; INTERFERON TYPE I; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; ORGANOPLATINUM COMPOUNDS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862773688     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1189-x     Document Type: Article

References (46)

1. J Banchereau RM Steinman 1998 Dendritic cells and the control of immunity Nature 392 6673 245 252 9521319 10.1038/32588 1:CAS:528:DyaK1cXitFWrsr8%3D
2. G Schreibelt J Tel KH Sliepen D Benitez-Ribas CG Figdor GJ Adema IJ de Vries 2010 Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy Cancer Immunol Immunother 59 10 1573 1582 20204387 10.1007/s00262-010-0833-1 1:CAS:528:DC%2BC3cXpt12lsL0%3D
3. I Treilleux JY Blay N Bendriss-Vermare I Ray-Coquard T Bachelot JP Guastalla A Bremond S Goddard JJ Pin C Barthelemy-Dubois S Lebecque 2004 Dendritic cell infiltration and prognosis of early stage breast cancer Clin Cancer Res 10 22 7466 7474 15569976 10.1158/1078-0432.CCR-04-0684 1:CAS:528:DC%2BD2cXhtVanur7K
4. E Hartmann B Wollenberg S Rothenfusser M Wagner D Wellisch B Mack T Giese O Gires S Endres G Hartmann 2003 Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer Cancer Res 63 19 6478 6487 14559840 1:CAS:528:DC%2BD3sXotV2is7g%3D
5. W Zou V Machelon A Coulomb-L'Hermin J Borvak F Nome T Isaeva S Wei R Krzysiek I Durand-Gasselin A Gordon T Pustilnik DT Curiel P Galanaud F Capron D Emilie TJ Curiel 2001 Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells Nat Med 7 12 1339 1346 11726975 10.1038/nm1201-1339 1:CAS:528:DC%2BD3MXovFKmsLc%3D
6. DI Gabrilovich J Corak IF Ciernik D Kavanaugh DP Carbone 1997 Decreased antigen presentation by dendritic cells in patients with breast cancer Clin Cancer Res 3 3 483 490 9815709 1:STN:280:DyaK1M%2FjsFejuw%3D%3D
7. C Menetrier-Caux G Montmain MC Dieu C Bain MC Favrot C Caux JY Blay 1998 Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor Blood 92 12 4778 4791 9845545 1:CAS:528:DyaK1cXotVWrtr4%3D
8. D Bell P Chomarat D Broyles G Netto GM Harb S Lebecque J Valladeau J Davoust KA Palucka J Banchereau 1999 In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas J Exp Med 190 10 1417 1426 10562317 10.1084/jem.190.10.1417 1:CAS:528:DyaK1MXnsVams7g%3D
9. S Wei I Kryczek L Zou B Daniel P Cheng P Mottram T Curiel A Lange W Zou 2005 Plasmacytoid dendritic cells induce CD8 + regulatory T cells in human ovarian carcinoma Cancer Res 65 12 5020 5026 15958543 10.1158/0008-5472.CAN-04- 4043 1:CAS:528:DC%2BD2MXltFemtLg%3D
10. TJ Curiel S Wei H Dong X Alvarez P Cheng P Mottram R Krzysiek KL Knutson B Daniel MC Zimmermann O David M Burow A Gordon N Dhurandhar L Myers R Berggren A Hemminki RD Alvarez D Emilie DT Curiel L Chen W Zou 2003 Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 9 5 562 567 12704383 10.1038/nm863 1:CAS:528:DC%2BD3sXjtlamtLc%3D
11. GJ Freeman AJ Long Y Iwai K Bourque T Chernova H Nishimura LJ Fitz N Malenkovich T Okazaki MC Byrne HF Horton L Fouser L Carter V Ling MR Bowman BM Carreno M Collins CR Wood T Honjo 2000 Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 7 1027 1034 11015443 10.1084/jem.192.7.1027 1:CAS:528:DC%2BD3cXntFSlt7o%3D
12. ME Keir MJ Butte GJ Freeman AH Sharpe 2008 PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677 704 18173375 10.1146/annurev. immunol.26.021607.090331 1:CAS:528:DC%2BD1cXltlWktrY%3D
13. JA Brown DM Dorfman FR Ma EL Sullivan O Munoz CR Wood EA Greenfield GJ Freeman 2003 Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J Immunol 170 3 1257 1266 12538684 1:CAS:528:DC%2BD3sXnvVOmtQ%3D%3D
14. S Radhakrishnan LT Nguyen B Ciric DR Ure B Zhou K Tamada H Dong SY Tseng T Shin DM Pardoll L Chen RA Kyle M Rodriguez LR Pease 2003 Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells J Immunol 170 4 1830 1838 12574348 1:CAS:528: DC%2BD3sXht12itLY%3D
15. N Selenko-Gebauer O Majdic A Szekeres G Hofler E Guthann U Korthauer G Zlabinger P Steinberger WF Pickl H Stockinger W Knapp J Stockl 2003 B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy J Immunol 170 7 3637 3644 12646628 1:CAS:528:DC%2BD3sXitFKlt7k%3D
16. Y Iwai M Ishida Y Tanaka T Okazaki T Honjo N Minato 2002 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci USA 99 19 12293 12297 12218188 10.1073/pnas.192461099 1:CAS:528:DC%2BD38XntlCksL8%3D
17. F Hirano K Kaneko H Tamura H Dong S Wang M Ichikawa C Rietz DB Flies JS Lau G Zhu K Tamada L Chen 2005 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 3 1089 1096 15705911 1:CAS:528:DC%2BD2MXhtVWnurg%3D
18. DB Flies L Chen 2007 The new B7 s: playing a pivotal role in tumor immunity J Immunother 30 3 251 260 17414316 10.1097/CJI.0b013e31802e085a 1:CAS:528:DC%2BD2sXjvVKitbc%3D
19. Y Zhang Y Chung C Bishop B Daugherty H Chute P Holst C Kurahara F Lott N Sun AA Welcher C Dong 2006 Regulation of T cell activation and tolerance by PDL2 Proc Natl Acad Sci USA 103 31 11695 11700 16864790 10.1073/pnas.0601347103 1:CAS:528:DC%2BD28XotFaitbc%3D
20. L Zitvogel G Kroemer 2009 Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects J Clin Invest 119 8 2127 2130 19620780 1:CAS:528:DC%2BD1MXpsFCltbY%3D
21. RA Lake BW Robinson 2005 Immunotherapy and chemotherapy-a practical partnership Nat Rev 5 5 397 405 10.1038/nrc1613 1:CAS:528:DC%2BD2MXjslertbk%3D
22. AK Nowak RA Lake AL Marzo B Scott WR Heath EJ Collins JA Frelinger BW Robinson 2003 Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 170 10 4905 4913 12734333 1:CAS:528:DC%2BD3sXjsVGqsro%3D
23. GV Shurin IL Tourkova R Kaneno MR Shurin 2009 Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J Immunol 183 1 137 144 19535620 10.4049/jimmunol.0900734 1:CAS:528:DC%2BD1MXnsVOrtb8%3D
24. WJ Lesterhuis CJ Punt SV Hato D Eleveld-Trancikova BJ Jansen S Nierkens G Schreibelt A de Boer CM Van Herpen JH Kaanders JH van Krieken GJ Adema CG Figdor IJ de Vries 2011 Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice J Clin Invest 121 8 3100 3108 21765211 10.1172/JCI43656 1:CAS:528:DC%2BC3MXhtVejur3L
25. J Tel R Torensma CG Figdor IJ de Vries 2011 IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1 J Invest Dermatol 131 4 900 906 21191414 10.1038/jid.2010.410 1:CAS:528:DC%2BC3MXjt1SrtL4%3D
26. H An J Hou J Zhou W Zhao H Xu Y Zheng Y Yu S Liu X Cao 2008 Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1 Nat Immunol 9 5 542 550 18391954 10.1038/ni.1604 1:CAS:528:DC%2BD1cXkvVOqtbo%3D
27. O Feinerman J Veiga JR Dorfman RN Germain G Altan-Bonnet 2008 Variability and robustness in T cell activation from regulated heterogeneity in protein levels Science 321 5892 1081 1084 18719282 10.1126/science.1158013 1:CAS:528:DC%2BD1cXhtVSitrbK
28. MK Pathak T Yi 2001 Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines J Immunol 167 6 3391 3397 11544330 1:CAS:528:DC%2BD3MXmvFGiuro%3D
29. YL Zhang YF Keng Y Zhao L Wu ZY Zhang 1998 Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases J Biol Chem 273 20 12281 12287 9575179 10.1074/jbc.273.20.12281 1:CAS:528:DyaK1cXjtlSgt7s%3D
30. RD Meng CC Shelton YM Li LX Qin D Notterman PB Paty GK Schwartz 2009 Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity Cancer Res 69 2 573 582 19147571 10.1158/0008-5472.CAN-08-2088 1:CAS:528:DC%2BD1MXltFShsQ%3D%3D
31. AR Khaled EJ Butfiloski ES Sobel J Schiffenbauer 1998 Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B Cell Immunol 185 1 49 58 9636682 10.1006/cimm.1998.1272 1:CAS:528: DyaK1cXjsl2qu7w%3D
32. D Nandan R Lo NE Reiner 1999 Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani Infect Immun 67 8 4055 4063 10417174 1:CAS:528: DyaK1MXkvVKltr4%3D
33. A Larange D Antonios M Pallardy S Kerdine-Romer 2009 TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation J Leukoc Biol 85 4 673 683 19164127 10.1189/jlb.0808504 1:CAS:528:DC%2BD1MXktVSrtbY%3D
34. H Dong SE Strome DR Salomao H Tamura F Hirano DB Flies PC Roche J Lu G Zhu K Tamada VA Lennon E Celis L Chen 2002 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 8 793 800 12091876 1:CAS:528:DC%2BD38Xls12msLo%3D
35. S Wintterle B Schreiner M Mitsdoerffer D Schneider L Chen R Meyermann M Weller H Wiendl 2003 Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis Cancer Res 63 21 7462 7467 14612546 1:CAS:528:DC%2BD3sXovVGltb0%3D
36. Y Ohigashi M Sho Y Yamada Y Tsurui K Hamada N Ikeda T Mizuno R Yoriki H Kashizuka K Yane F Tsushima N Otsuki H Yagita M Azuma Y Nakajima 2005 Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 8 2947 2953 15837746 10.1158/1078-0432.CCR-04-1469 1:CAS:528:DC%2BD2MXjtlejt7k%3D
37. J Hamanishi M Mandai M Iwasaki T Okazaki Y Tanaka K Yamaguchi T Higuchi H Yagi K Takakura N Minato T Honjo S Fujii 2007 Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci USA 104 9 3360 3365 17360651 10.1073/pnas.0611533104 1:CAS:528:DC%2BD2sXjtVWlt7s%3D
38. C Blank TF Gajewski A Mackensen 2005 Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 54 4 307 314 15599732 10.1007/s00262-004-0593-x 1:CAS:528:DC%2BD2MXhtVanuro%3D
39. RH Thompson MD Gillett JC Cheville CM Lohse H Dong WS Webster KG Krejci JR Lobo S Sengupta L Chen H Zincke ML Blute SE Strome BC Leibovich ED Kwon 2004 Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci USA 101 49 17174 17179 15569934 10.1073/pnas.0406351101 1:CAS:528:DC%2BD2cXhtFagu7fM
40. C Blank I Brown AC Peterson M Spiotto Y Iwai T Honjo TF Gajewski 2004 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells Cancer Res 64 3 1140 1145 14871849 10.1158/0008-5472.CAN-03-3259 1:CAS:528:DC%2BD2cXhtFCgtrs%3D
41. T Yamazaki H Akiba H Iwai H Matsuda M Aoki Y Tanno T Shin H Tsuchiya DM Pardoll K Okumura M Azuma H Yagita 2002 Expression of programmed death 1 ligands by murine T cells and APC J Immunol 169 10 5538 5545 12421930 1:CAS:528:DC%2BD38Xoslyqu7s%3D
42. TL Sumpter AW Thomson 2011 The STATus of PD-L1 (B7-H1) on tolerogenic APCs Eur J Immunol 41 2 286 290 21267998 10.1002/eji.201041353 1:CAS:528:DC%2BC3MXpvFCjtg%3D%3D
43. SJ Wolfle J Strebovsky H Bartz A Sahr C Arnold C Kaiser AH Dalpke K Heeg 2011 PD-L1 expression on tolerogenic APCs is controlled by STAT-3 Eur J Immunol 41 2 413 424 21268011 10.1002/eji.201040979
44. P Zhang DM Su M Liang J Fu 2008 Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis Mol Immunol 45 5 1470 1476 17920123 10.1016/j.molimm.2007.08.013 1:CAS:528:DC%2BD1cXhtF2ltg%3D%3D
45. C Aspord A Pedroza-Gonzalez M Gallegos S Tindle EC Burton D Su F Marches J Banchereau AK Palucka 2007 Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4 + T cells that facilitate tumor development J Exp Med 204 5 1037 1047 17438063 10.1084/jem.20061120 1:CAS:528:DC%2BD2sXlsFSjtr4%3D
46. C Manegold D Gravenor D Woytowitz J Mezger V Hirsh G Albert M Al-Adhami D Readett AM Krieg CG Leichman 2008 Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer J Clin Oncol 26 24 3979 3986 18711188 10.1200/JCO.2007.12.5807 1:CAS:528:DC%2BD1cXhtFajtr%2FM